Rapid Onset of Diabetic Ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 5, 2017, Pages 1451-1453

  Quarella, Marino ^a   Walser, Daniel ^a   Brändle, Michael ^a   Fournier, Jean Yves ^a   Bilz, Stefan ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRONE; EMPAGLIFLOZIN; GLICLAZIDE; GROWTH HORMONE; HEMOGLOBIN A1C; INFUSION FLUID; INSULIN; INSULIN GLARGINE; METFORMIN; PARACETAMOL; SITAGLIPTIN; SOMATOMEDIN C; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; FATTY ACID; GLUCAGON; GLUCOSIDE; KETONE BODY; SODIUM GLUCOSE COTRANSPORTER 2;

ACROMEGALY; ADULT; ARTICLE; ASTHENIA; CASE REPORT; COARSE FACE; DETERIORATION; DIABETIC KETOACIDOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; GROWTH HORMONE SECRETING ADENOMA; HEADACHE; HUMAN; HYPERGLYCEMIA; KETONURIA; LOSS OF APPETITE; LOW BACK PAIN; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYSOMNOGRAPHY; POLYURIA; PRIORITY JOURNAL; PROGNATHIA; SLEEP DISORDERED BREATHING; SNORING; TRANSSPHENOIDAL SURGERY; ADENOMA; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; METABOLISM; SEVERITY OF ILLNESS INDEX;

ADENOMA; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; GLICLAZIDE; GLUCAGON; GLUCOSIDES; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KETONE BODIES; MALE; METFORMIN; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85019099877     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2017-00082     Document Type: Article

References (10)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
2. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication oftreatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693.
3. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose toketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849-2852.
4. Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, De Fronzo RA, Norton L, Abdul-Ghani M. Dapagliflozin enhancesfat oxidation and ketone production in patients with type 2diabetes. Diabetes Care. 2016;39(11):2036-2041.
5. Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibitionof the glucose transporter SGLT2 with dapagliflozin in pancreaticalpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-517.
6. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis:a predictable, detectable, preventable safety concern withSGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642.
7. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, Delemer B; French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, evolution:data from the French Acromegaly Registry. Eur J Endocrinol. 2011;164(6):877-884.
8. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current andemerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016;27(7):470-483.
9. Keller U, Schnell H, Girard J, Stauffacher W. Effect of physiologicalelevation of plasma growth hormone levels on ketone body kineticsand lipolysis in normal and acutely insulin-deficient man. Diabetologia. 1984;26(2):103-108.
10. Yoshida N, Goto H, Suzuki H, Nagasawa K, Takeshita A, Okubo M, Miyakawa M, Mori Y, Fukuhara N, Nishioka H, Yamada S, Takeuchi Y. Ketoacidosis as the initial clinical condition in ninepatients with acromegaly: A review of 860 cases at a single institute. Eur J Endocrinol. 2013;169(1):127-132.